TOKYO -- Takeda Pharmaceutical will sell five prescription products to China's Hasten Biopharmaceutic in a $322 million deal as Japan's top drugmaker continues to slash debt from its acquisition of Ireland-based peer Shire.
The transaction is slated to close by the end of June and covers cardiovascular and metabolism treatments sold in mainland China, including the Ebrantil blood pressure reducer.
